Celsion Corporation - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
CLSN Nasdaq 2834 http://celsion.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Celsion Corporation

Celsion Corporation Reports First Quarter 2022 Financial Results and Provides Business Update - May 16th, 2022 12:00 pm
Celsion Corporation Highlights Pipeline Progress in Its Lead Development Candidates - May 10th, 2022 12:30 pm
Celsion Corporation to Hold First Quarter 2022 Financial Results and Business Update Conference Call on Monday, May 16, 2022 - May 9th, 2022 12:30 pm
Celsion's Formulated DNA Plasmid COVID-19 Vaccine Candidate Shows Activity Against Two Strains - Apr 21st, 2022 7:24 pm
Celsion Corporation Highlighted its PLACCINE Vaccine Platform Technology During Oral Presentation at the World Vaccine Congress - Apr 21st, 2022 3:30 pm
Celsion and Medidata Present Findings on Use of Synthetic Control Arm to Estimate Treatment Effect in Ovarian Cancer Trial at 2022 AACR Annual Meeting - Apr 14th, 2022 12:30 pm
Celsion Corporation to Highlight its PLACCINE Platform Technology During Oral Presentation at the World Vaccine Congress - Apr 12th, 2022 12:30 pm
Celsion Corporation Announces Closing of $7.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules - Apr 8th, 2022 8:30 pm
Celsion and Medidata to Present Findings on Use of Synthetic Control Arm to Estimate Treatment Effect in Ovarian Cancer Trial - Apr 6th, 2022 12:30 pm
CELSION CORPORATION ANNOUNCES $7.0 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET UNDER NASDAQ RULES - Apr 6th, 2022 12:30 pm
CLSN: DSMB Recommends Continuing to Dose Patients in OVATION 2 Study… - Apr 5th, 2022 10:15 am
Celsion Corporation Reported Cash Position of $56.9 million at December 31, 2021 - Apr 1st, 2022 12:00 pm
Celsion Corporation Reports 2021 Financial Results and Provides Business Update - Mar 31st, 2022 12:30 pm
Celsion Corporation to Hold Year-End 2021 Financial Results and Business Update Conference Call on Thursday, March 31, 2022 - Mar 24th, 2022 1:00 pm
Celsion Receives $1.4 Million from Sale of its New Jersey State Net Operating Losses - Feb 28th, 2022 2:00 pm
Celsion Corporation Announces Stock Consolidation - Feb 28th, 2022 1:30 pm
Celsion Reports Data Safety Monitoring Board Unanimous Recommendation to Continue Dosing Patients in the Phase II Portion of the OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer - Feb 17th, 2022 1:30 pm
Celsion Corporation Advances Proof of Concept to Non-human Primate Challenge Study Against SARS-CoV-2 with In-Process Vaccine Candidate - Jan 31st, 2022 1:00 pm
Celsion Corporation Announces Pricing of $30 Million Registered Direct Offerings of Convertible Redeemable Preferred Stock - Jan 13th, 2022 10:30 pm
Celsion Corporation Invited to Present Poster at Cytokine-Based Cancer Immunotherapies Summit - Nov 29th, 2021 1:30 pm